Bristol Myers Squibb extends modest rebound, shares tick higher in S&P 500 healthcare trade

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-23, 20:54.

Bristol Myers Squibb (US0897961004) trades firmer on the NYSE on Tuesday, with shares recently quoted around the mid-55 dollar mark in S&P 500 healthcare trading according to consolidated price data. Investors continue to reassess the reshaped income profile and sector-relative valuation after this year’s dividend reset and a weak start to 2026.

What the latest trading shows

Recent intraday data place Bristol Myers Squibb shares near 55 to 56 US dollars, with a last price of about 55.25 dollars and a gain of just over 1 percent versus the previous close in New York trade earlier on Tuesday, based on aggregated quote services.

Market trackers such as TradingKey and other consolidated feeds indicate a market capitalization in the area of 112 billion dollars at those levels, leaving the stock positioned in the mid-cap range of the large global pharmaceutical cohort and firmly within the S&P 500 healthcare sector peer group.

Analyst stance and sector comparison

Consensus data compiled by several analyst aggregators show Bristol Myers Squibb with an overall Hold to moderate Buy stance, and an average one-year price objective in the low 60 dollar range, implying single-digit to low double-digit percentage upside from current trading levels according to those summaries of Wall Street research.

In comparative terms the equity trades at a discount on simple valuation metrics such as price-to-earnings versus U.S. peers Pfizer and Merck, a gap that many sector strategists link to patent-expiry concerns and the company’s need to demonstrate that its late-stage pipeline and recent acquisitions can sustain earnings and cash flow over the second half of the decade.

How Bristol Myers makes its money

Bristol Myers Squibb generates the bulk of its revenue from prescription medicines in oncology, cardiovascular and immunology, including Eliquis for stroke prevention in atrial fibrillation, the immunotherapy Opdivo in various cancer indications and the multiple myeloma drug Revlimid, alongside a broader portfolio of specialty pharmaceuticals.

Where the shares trade today

The Bristol Myers Squibb shares (US0897961004) most recently changed hands on the NYSE at around 55.25 US dollars in Tuesday trading, based on consolidated price data for 2026-06-23, 09:52 Eastern Time.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, an offer or a solicitation to buy or sell any securities. Figures and dates are based on sources believed to be reliable but cannot be guaranteed.